Approximately 15 to 20% of patients with breast cancer (BC) have tumors with elevated levels of human epidermal growth factor receptor 2 (HER2), which are associated with an aggressive clinical phenotype and poor prognosis [1, 2]. The gene discussed is ERBB2; the disease is breast cancer.